IRVINE, Calif., April 06, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE:BIOA). Investors who purchased shares pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or on the open market from January 23, 2017 through March 16, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 17, 2017 lead plaintiff motion deadline.
If you purchased BioAmber shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The complaint states that throughout the Class Period, BioAmber made materially false and/or misleading statements and/or failed to disclose that a large customer of the Company that was expected to purchase $2.8 million of succinic acid in the fourth quarter of 2016 postponed the order to 2017; and as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 



